CLINEXEL at IPA-DSB International Conference on Cell Therapy in India
CLINEXEL participated in the One-Day International Conference on “Navigating Cell Therapy in India: Regulatory Pathways, Market Dynamics & Opportunities”, held on 6th December 2025 in New Delhi, organized by the Indian Pharmaceutical Association – Delhi State Branch (IPA-DSB).
The conference focused on collaborative ecosystems and global market opportunities in the rapidly evolving field of cell and gene therapy clinical research and advanced therapies.
Dr. Deepa Arora, CEO of CLINEXEL, served as a panelist in the discussion:
“Commercialization of Cell Therapy – Market Access for Global Competitiveness”
The panel explored strategies to strengthen India’s role in the global cell therapy market, including:
- Regulatory alignment
- Scalable manufacturing
- Sustainable commercialization models
- Global competitiveness in advanced therapies
Dr. Deepa highlighted the importance of collaboration among regulators, biotechnology companies, CROs, clinicians, and healthcare providers to enable efficient clinical translation and broader patient access.
Accelerating cell and gene therapy clinical trials, CLINEXEL enables global clinical trial access through innovative, patient-centric approaches and decentralized clinical trial (DCT) models.
Our expertise in:
- Multi-Regional Clinical Trials (MRCTs)
- CGT clinical development
- Advanced Therapy Medicinal Products (ATMP) trials
- Precision medicine clinical research
ensures:
- Faster patient recruitment
- Streamlined clinical trial operations
- Optimized timelines from study start to approval
- Efficient global clinical trial execution
By integrating advanced therapy medicinal products (ATMP) trials, precision medicine, and robust global regulatory strategies, CLINEXEL expands worldwide participation and supports the efficient delivery of gene therapy and cell therapy clinical research, helping bring breakthrough treatments to patients faster.